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Objective. Use of cancer cases from registries and PMSI claims database to estimate D´ epartement-speciﬁc incidence of four major
cancers. Methods. Case extraction used principal diagnosis then surgery codes. PMSI cases/registry cases ratios for 2004 were
modelled then D´ epartement-speciﬁc incidence for 2007 estimated using these ratios and 2007 PMSI cases. Results. For 2007, only
colon-rectum and breast cancer estimations were satisfactorily validated for infranational incidence not ovary and kidney cancers.
For breast, the estimated national incidence was 50,578 cases and the incidence rate 98.6 cases per 100,000 person per year. For
colon-rectum, incidence was 21,172 in men versus 18,327 in women and the incidence rate 38 per 100,000 versus 24.8. For ovary,
the estimated incidence was 4,637 and the rate 8.6 per 100,000. For kidney, incidence was 6,775 in men versus 3,273 in women and
the rate 13.3 per 100.000 versus 5.2. Conclusion. Incidence estimation using PMSI patient identiﬁers proved encouraging though
still dependent on the assumption of uniform cancer treatments and coding.
1.Introduction
Inbeingresponsibleforabout350,000newcasesand150,000
deaths yearly in France, cancer is a major health problem
and its surveillance the utmost public health concern.
Regarding surveillance, FRANCIM, the French network of
cancer registries, is responsible for exhaustive collections of
cancer cases in 10 to 14 French D´ epartements (depending
on the cancer type) corresponding to 15% to 20% of
the French population. However, estimating epidemiological
indicators at the scale of whole D´ epartements over the
country is necessary not only to reveal etiological factors
and geographical or social discrepancies but also to plan the
needs in terms of medical resources (prevention, treatment,
and surveillance).
Over the previous ten years or so, FRANCIM and the
Department of Biostatistics of the Hospices Civils de Lyon
havebeenprovidingnationalestimationsofcancerincidence
[1, 2]. Their usual approach to produce these estimations is
to use registry incidence data together with C´ epiDC mortal-
ity data (Centre d’Epid´ emiologie sur les Causes m´ edicales
de D´ ec` es) [3]. The principle is to calculate a mean ratio2 Journal of Cancer Epidemiology
betweenincidenceandmortalityinanareacoveredbycancer
registries then use that ratio with national mortality data to
derive an estimation of national incidence. While the mean
ratio estimated in a registry area can be reasonably consid-
ered as representative of the ratio for the whole country, the
same is not true at the level of a single D´ epartement because
this ratio may be highly variable between D´ epartements and
because identical incidence values do not necessarily lead to
identical mortalities. Indeed, a great number of factors are
able to aﬀect patient survival and generate heterogeneity of
the ratio between D´ epartements: diﬀerences in patient man-
agement (diagnostic or therapeutic procedures), prevention
or screening policies, or compliance of the population with
these policies. Therefore, because incidence and mortality
cannot be used to provide D´ epartement-speciﬁc incidence
estimations, a new approach should be sought for.
One interesting source of data with a nationwide cov-
erage has been recently used together with registry data to
estimate D´ epartement-speciﬁc cancer incidence: the hospital
database of the Programme de M´ edicalisation des Syst` emes
d’Information M´ edicale (PMSI) [4–6]. This medicoadmin-
istrative database is held to help manage health institutions
and provide budget estimates.
Ap r e v i o u sw o r k[ 7] has discussed the problem of using
hospital stays from PMSI data to estimate D´ epartement-
speciﬁc incidence of breast cancer. However, the constant
improvement of the quality of patient identiﬁcation in PMSI
data using a single-patient identiﬁer makes it possible now to
use patient-speciﬁc rather than stay-speciﬁc data
In the present paper, our objective was to estimate
D´ epartement-speciﬁc incidence of colon-rectum, breast,
kidney, and ovary cancers for 2007 using mean ratios of
PMSI-extracted cases to registry-extracted (incident) cases.
2.MaterialsandMethods
2.1. PMSI Database, Hospital Stay-Speciﬁc Data, and Patient-
Speciﬁc Data. The French Agence Technique de l’Infor-
mation sur l’Hospitalisation (ATIH) made available its data
on all short stays in all health institutions over France for
2002–2007. In our analyses, we kept the variables related to
personal characteristics (sex, age, and code of the residence
area), hospital stay (stay number and principal diagnosis
according to the International Classiﬁcation of Diseases
(ICD-10)[8],andmedicalproceduresaccordingtotheCata-
logue des Actes M´ edicaux (CdAM) until 2004 [9] and to the
new Classiﬁcation Commune des Actes M´ edicaux (CCAM)
[10] from 2004 to 2007, plus an anonymous alphanumerical
patient identiﬁer [11, 12] to allow chaining of hospital
stays of the same patient in successive institutions. That
identiﬁer is systematically generated by procedure FOIN
(Fonction d’Occultation des Informations Nominatives) in
all French health institutions since 2001. Hospital stays with
noavailablepatientidentiﬁerwereexcludedfromthepresent
analyses.
Two algorithms were independently used to extract
hospital stays to analyze. The ﬁrst one extracted all stays
with cancer as principal diagnosis. The corresponding CIM
10 codes were C18 to C21 for colon-rectum cancer, C50
for breast cancer, C56 and C57.0 to C57.4 for ovary cancer,
and C64 to C66 plus C68 for kidney cancer. The second
algorithm extracted stays with cancer as principal diagnosis
and with surgical procedures for cancer. Using CdAM and
CCAM codes, the latter extraction considered 95 procedures
for colon-rectum cancer, 31 for breast cancer, 114 for ovary
cancer, and 44 for kidney cancer.
After each type of extraction, hospital stays were ordered
by their serial numbers to spot the ﬁrst stay of each patient,
then only these stays were kept for analysis. These stays
were then counted over each D´ epartement by age group:
ten groups for colon-rectum cancer (15–44, 45–49, 50–54,
..., 80–84, and ≥85yrs), eleven groups for kidney cancer
in women (15–39, 40–44, 45–49, ..., 80–84, and ≥85yrs),
and thirteen groups for each of breast cancer, ovary cancer,
and kidney cancer in men (15–29, 30–34, 35–39, ..., 80–84,
≥85yrs).
2.2. Registry Incident Cancer Cases. FRANCIM network
made available the data on incident cancer cases registered in
2004 (the most recent and checked data set when the present
study was initiated).
Cancer sites were determined according to the Interna-
tional Classiﬁcation of Diseases for Oncology, third version
(ICD-O-3) [8] and corresponded to invasive tumors. These
codes were: C18 to C21 for colon-rectum cancers, C50 for
breast cancer, C56 and C57.0 to C57.4 for ovary cancer
(excluding morphological codes 8442/3, 8451/3, 8461/3,
8462/3, 8472/3, and 8473/3), and C64 to C66 plus C68 for
kidney cancer.
The cancer registries used were those of eleven D´ epa-
rtements: Calvados, Cˆ ote d’Or, Doubs, H´ erault, Is` ere, Loire-
Atlantique, Bas-Rhin, Haut-Rhin, Saˆ one-et-Loire, Somme,
and Tarn. Incidents cases of cancers were counted by the
same age group as for hospital stays.
2.3. Modeling the Ratio of PMSI Cases to Incident Cases.
Our approach was to model, in function of age, the PMSI
cases/incident cases ratio; that is, the ratio of the number of
patients with hospital stays for cancer present in the PMSI
database to the number of incident cases present in the
registries. This ratio was obtained from D´ epartements where
the two sources of information exist (i.e., D´ epartements with
aregistry).ItwasthenappliedtoPMSIdataofD´ epartements
without registry, in order to estimate cancer incidence in
these areas. This ratio was obtained from registry and PMSI
data of year 2004; it was then applied to PMSI data for 2007
to derive D´ epartement-speciﬁc incidence for 2007.
The method adopted to model that ratio was detailed
by Remontet et al. [7]. It is a calibration method where
incidence, as obtained from cancer registries, is considered
as reference or “true” value whereas PMSI cases allow only
an approximation of this value. More precisely, the ratio is
modelled as a function of age (eﬀects smoothed using cubic
regression spline) and D´ epartement (considered as random
eﬀect).
Further, to estimate the PMSI cases/incident cases ratio,
a data quality criterion was required: that the chaining rate
be greater or equal to 95%. This chaining rate was deﬁned asJournal of Cancer Epidemiology 3
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Figure 1: Breast cancer-PMSI cases/incidence case ratio by age classes by D´ epartement in year 2004.
the ratio of the number of stays with personal identiﬁer to
the total number of stays.
The analysis was carried out for the four cancer sites in
women but only for colon-rectum cancer and kidney cancer
in men. Whenever the number of cancer cases was small, it
was not possible to take into account between-D´ epartement
variability in areas with registries. We had then to sum
up data from several D´ epartements and calculate the PMSI
cases/incident cases ratio per age group over the entire zone.
The overall national incidence was calculated by sum-
ming all D´ epartement estimations. For validation, we com-
pared these national incidence values to FRANCIM values
previously obtained by modeling the incidence/mortality
ratio [1, 2, 13].
2.4. Validation of the Estimations. Validation was carried
out through three steps. In step 1, the PMSI cases/incident
cases ratio was calculated over all ages using each algo-
rithm per cancer site-sex combination and D´ epartement.
Indeed, D´ epartement-speciﬁc estimations stemming from
this approach are invalid unless the ratio is homogeneous
between D´ epartements (always >1o ra l w a y s<1). In step 2,
the observed ratio for a given age group and D´ epartement
was graphically compared to the modelled mean ratio over
all D´ epartements with registries (Figure 1). However, to be
applicable to all D´ epartements, the modelled mean ratio
should not suﬀer a “D´ epartement eﬀect”. In the presence
of this eﬀect, the observed ratios per age groups tend
to be systematically higher or lower than the mean ratio
whereas in its absence, the observed ratios are distributed
around the mean ratio. For cancer sites with high incidence
(breast, colon-rectum), step 3 was a cross-validation [7]. The
incidence in a given D´ epartement with registry is estimated
from PMSI data together with the PMSI cases/incident cases
ratio obtained by a model from which the data of that
D´ epartement were excluded. A comparison between the
number of observed cases and the number of predicted cases
yields a Prediction Error (PE) [7]. Under hypothesis H0 of
a correct prediction, the PE obeys a χ2 rule whose degree
of freedom is equal to the number of age groups. A 5% α-
risk was adopted to set the critical value for rejecting H0.F o r
cancer with low incidence (ovary, kidney), cross-validation
could not be used, because it was diﬃcult to determine
the statistical distribution of the PE and so only graphical
validation was done. In addition, a comparison between the
total numbers of observed and predicted cases was carried4 Journal of Cancer Epidemiology
Table 1: Registry data and PMSI data used for estimations of the ratio in 2004. Validation steps of prediction of incidence using each
algorithm.
Registry data PMSI data Validation steps
Cancer site Number of
D´ epartements Observed cases Algorithm Extracted cases
Number of
D´ epartements
with ratio <1
D´ epartement
eﬀect
Cross-Validation
PE1 χ22
Colon-Rectum
Men 8 2,009 1 2,660 0 No 0 0
2 1,850 7 Yes 0 2
Women 8 1,625 1 2,042 0 No 0 0
2 1,373 7 Yes 2 1
Breast
Women 6 3,946 1 4,624 0 No 0 0
2 4,037 2 No 2 0
Ovary
Women 6 390 1 529 0 No NA3 NA
2 383 3 No NA NA
Kidney NA NA
Men 8 657 1 786 0 No NA NA
2 573 7 No NA NA
Women 5 231 1 284 0 No NA NA
2 202 3 No NA NA
1Prediction error: number of registries presenting a statistically signiﬁcant diﬀerence between observed and predicted cases by age group.
2χ2: Number of registries presenting a statistically signiﬁcant diﬀerence between total observed and total predicted cases predicted.
3Not applicable.
out (χ2 with one degree of freedom). A relative error (RE)
was calculated as the diﬀerence between the observed and
predicted cases divided by the number of observed cases.
Theresultsweremappedasstandardizedincidenceratios
(SIR) using software MAPINFO (version 7.0).
3. Results
In 2004, the PMSI database was including 20,721,587
hospital stays of which 718,044 stays had cancer as principal
diagnosis. The chaining rate of those stays was 96.4%. In
2007, there were 21,201,102 stays of which 721,823 had
cancer as principal diagnosis and the chaining rate was 99%.
To illustrate our validation procedure the analyses rel-
ative to breast cancer were plainly detailed whereas those
relative to the other cancer sites were less detailed.
3.1. BreastCancer. Six registries wereselected toestimate the
incidenceofbreastcancer(Table 1).FourD´ epartementswith
registries were excluded because, in 2004, their chaining rate
was too low; it ranged between 49.7% and 94.9%.
Table 1 shows the total number of cases by cancer
site and case-extraction algorithm as well as the three
steps of estimate validation: homogeneity of the PMSI
cases/incident cases ratio through D´ epartements with ratio
<1, the D´ epartement eﬀect, and the cross-validation.
Regarding the homogeneity of the ratio, the results show
that algorithm 2 was inadequate. Indeed, whereas with
algorithm 1 the number of PMSI cases was always higher
thantheincidentcasesinallD´ epartements,withalgorithm2,
the former number was sometimes higher (2 D´ epartements)
and sometimes lower (4 D´ epartements) than the latter.
Regarding the D´ epartement eﬀect, Figure 1 presents, for
each D´ epartement with registries and for algorithm 1, the
observed ratio by age group as well as the modelled mean
ratio over all D´ epartements with registries. The absence
of heterogeneity in that ratio between D´ epartements is
illustrated by the fact that there was no D´ epartement in
which the ratio per age group was systematically higher or
lower than the modelled mean ratio (though D´ epartement
Calvados tend to be systematically higher than the modelled
mean ratio). It can be therefore concluded that there is no
D´ epartement eﬀect for breast cancer with algorithm 1 (the
variance of the random eﬀect was small: 0.023).
Regarding the cross-validation, Table 2 presents the
detailed results for breast cancer. With algorithm 1, the
diﬀerences between the observed and the predicted number
of cases per age group (PEs) were small whereas with
algorithm 2, two D´ epartements displayed large diﬀerencesJournal of Cancer Epidemiology 5
Table 2: Cross-validation of breast cancer estimations for each algorithm (PMSI data and registry data correspond to year 2004).
Algorithm 1 Algorithm 2
D´ epartement Observed cases PMSI cases Predicted cases PE 1 χ22 RE3 PMSI cases Predicted cases PE1 χ22 RE3
Calvados 449 566 487 8 3.0 +8.5 493 480 27.4 2.0 + 6.8
Doubs 409 495 426 12.8 0.7 +4.2 401 398 34.3 0.3 −2.7
H´ erault 919 1,031 872 7.1 2.5 −5.1 900 880 12 1.8 −4.3
Is` ere 901 1,039 873 9 0.9 −3.1 901 869 8.9 1.2 −3.5
Loire-Atlantique 963 1,138 959 5 0.0 −0.4 1,036 1,019 10.9 3.1 +5.8
Tarn 305 355 306 7.3 0.0 +0.3 306 304 10.1 0.0 −0.5
Total 3,946 4,624 3,923 4,037 3,950
1PE: prediction error, under the hypothesis that prediction is correct, PE follows a χ2 l a ww i t h1 0d e g r e e so ff r e e d o m ;t h a ti s ,w i t ha5 %α-risk, if PE >18.3
then the prediction is not correct for that D´ epartement.
2χ2 with one degree of freedom, threshold value 3.84.
3RE: relative error; that is, predicted cases-observed cases/observed.
Table 3: National estimations of the number of cancer cases and of world-standardized incidence rates (per 100,000 persons) in 2007 based
on the modeling of the ratio of PMSI cases to incidence cases using algorithm 1. Comparison with FRANCIM national estimates based on
the modeling of the ratio incidence/mortality.
National estimates based on the PMSI cases/Incident cases ratio FRANCIM estimates
Cancer site Number of cases Standardized rates1 Number of cases Standardized rates1
Colon-rectum
Men 21,172 38.0 20,453 37.4
Women 18,327 24.8 18,052 24.4
Breast
Women 50,578 98.6 52,492 103.4
Ovary
Women 4,637 8.6 4,402 7.9
Kidney
Men 6,775 13.3 6,328 13
Women 3,273 5.2 3,201 5.3
1standardized on world population age structure.
especially concerning the last age group. Furthermore, the
diﬀerence between the total observed and the total predicted
cases (χ2) was small with algorithm 1: thus, this algorithm 1
may be reliably used for breast cancer estimates.
Table 3 shows the national estimations obtained by ad-
ding the estimations obtained from all D´ epartements by
algorithm 1 as well as the national estimations elaborated by
FRANCIM [14] through the use of the incidence/mortality
ratio [1, 2, 13]. Comparing these two estimations was one
way to validate the results of the present analysis.
The national incidence of breast cancer for 2007 was
estimated at 50,578 cases. The World age-standardized
incidence rate (WASR) was 98.6 cases per 100,000 and varied
between D´ epartements from 71.4 to 127.1 (Table 4).
3.2. Colon-Rectum Cancer. To estimate D´ epartement-speci-
ﬁcincidenceofcolon-rectumcancer,weuseddatafromeight
registries. Datafromthree D´ epartements withregistries were
excluded because the chaining rate in 2004 was too poor
(72.6% to 94.9%).
Irrespective of sex, the PMSI cases/incident cases ratios
obtained with algorithm 1 were homogeneous (the variance
of the random eﬀect was small: 0.024), which was not the
case with algorithm 2 for which there was a D´ epartement
eﬀect in both gender. In addition, contrary to algorithm
1, cross-validation invalidated the estimations made with
algorithm 2 in two D´ epartements. Thus, we present only
estimations made with algorithm 1. The national incidence
for 2007 was estimated at 21,172 cases in men and 18,327
cases in women. The estimated national WASR was 38 cases
per 100,000 in men and 24.8 in women. At the national
level, our estimations were in high agreement with those of
FRANCIM (40.8 cases per 100,000 in men and 24.8 cases per
100,000 in women).
Among D´ epartements, the WASR ranged from 23.1 to
48.9 in men and from 17.4 to 31.3 in women.
3.3. Ovary Cancer. The estimations of D´ epartement-speciﬁc
incidence used six cancer registries. Three D´ epartements
with registries were excluded because the chaining rate was
too poor (80% to 93.5%).
The PMSI cases/incident cases ratio carried out with
algorithm 1 yielded homogeneous ratio between D´ epar-
tements, and no D´ epartement eﬀect was observed. This was6 Journal of Cancer Epidemiology
Table 4: World standardized incidence rates in all French D´ epartements (per 100,000 persons) in year 2007.
Colon-rectum
D´ epartement Code Male Female Breast
Ain 01 35.1 25.2 82
Aisne 02 44.1 26.1 103.2
Allier 03 38.9 27.4 81.8
Alpes-de-Haute-Provence 04 43.5 24.3 98.1
Hautes-Alpes 05 35.9 17.4 94.3
Alpes-Maritimes 06 37 26.1 98.6
Ard` eche 07 44.3 26 84.9
Ardennes 08 43.6 19.5 95.7
Ari` ege 09 40.5 25.8 80.7
Aube 10 28.8 23.3 84.1
Aude 11 35.2 24.3 95.6
Aveyron 12 30.3 23 80.3
Bouches-du-Rhˆ one 13 37.7 26.5 111.6
Calvados 14 36.6 20.3 92.5
Cantal 15 27.3 20.5 83.3
Charente 16 38.2 24.8 93.5
Charente-Maritime 17 43.8 27 92.5
Cher 18 40.2 27.7 94.9
Corr` eze 19 32.9 22.9 84.7
Cˆ ote-d’Or 21 35.7 22.7 84.9
Cˆ otes-d’Armor 22 40.3 28.7 95.1
Creuse 23 41 27 83.2
Dordogne 24 40.8 22.8 91.6
Doubs 25 34.5 24.7 89.6
Drˆ ome 26 37.3 28.3 97.9
Eure 27 43.4 25.2 97.2
Eure-et-Loir 28 38.2 25.9 101.1
Finist` ere 29 39.3 24 94.4
Corse-du-Sud 2A 48.9 29.2 79.5
Haute-Corse 2B 23.1 22.5 107.1
Gard 30 40.8 23.6 109
Haute-Garonne 31 34.4 22.5 96.8
Gers 32 34.6 26 79.7
Gironde 33 37.9 28 93.6
H´ erault 34 38.6 22.7 94
Ille-et-Vilaine 35 30.8 19.6 90.3
Indre 36 34.6 27.6 86.8
Indre-et-Loire 37 35 27.5 108.8
Is` ere 38 35.9 23.4 96.3
Jura 39 36.3 19.5 81.8
Landes 40 37.5 24.4 92.7
Loir-et-Cher 41 37.9 27.6 104.9
Loire 42 40.7 27.1 97.5
Haute-Loire 43 43 25.3 77.9
Loire-Atlantique 44 39.8 23.7 108.4
Loiret 45 40 22.7 96.7
Lot 46 35.3 22.3 83.3
Lot-et-Garonne 47 32.3 24.2 71.4
Loz` ere 48 39.8 20.9 98.1Journal of Cancer Epidemiology 7
Table 4: Continued.
Colon-rectum
D´ epartement Code Male Female Breast
Maine-et-Loire 49 42.8 25.7 127.1
Manche 50 32.6 18.6 86.8
Marne 51 38.9 27.2 106.6
Haute-Marne 52 41.2 18.4 99.4
Mayenne 53 42.2 20.4 91.4
Meurthe-et-Moselle 54 41.7 26.5 109.9
Meuse 55 34.8 31.3 101.7
Morbihan 56 38.1 23.3 92
Moselle 57 41.6 24.4 101.8
Ni` evre 58 48.6 22.8 80.6
Nord 59 41.6 26.2 102
Oise 60 38.8 26.3 93.7
Orne 61 41.5 27.4 112.6
Pas-de-Calais 62 40.5 27.7 97.6
Puy-de-Dˆ ome 63 42.2 24.7 87.7
Pyr´ en´ ees-Atlantiques 64 37.4 22.9 91.8
Hautes-Pyr´ en´ ees 65 39.6 23.8 83.8
Pyr´ en´ ees-Orientales 66 40.9 24 96.3
Bas-Rhin 67 38.1 23.5 97.7
Haut-Rhin 68 35.3 25.3 86.8
Rhˆ one 69 39.9 24.6 99.3
Haute-Saˆ one 70 42 28.5 100.5
Saˆ one-et-Loire 71 43.4 25.3 97.9
Sarthe 72 31.2 19.8 103.9
Savoie 73 35.3 23.5 88.8
Haute-Savoie 74 29 17.8 96.3
Paris 75 35.8 25.5 117.6
Seine-Maritime 76 34.9 24.3 103.5
Seine-et-Marne 77 37.5 30.2 101.6
Yvelines 78 34.9 26.1 107.1
Deux-S` evres 79 44.1 23.4 91.3
Somme 80 44.6 23.6 104.7
Tarn 81 28.7 21.2 87.5
Tarn-et-Garonne 82 34.1 23.6 108.8
Var 83 36.3 24.6 109.1
Vaucluse 84 45.6 25.7 101.6
Vend´ ee 85 40.2 25.3 103.6
Vienne 86 39.7 20.1 93.7
Haute-Vienne 87 39.6 24.8 89.3
Vosges 88 37.7 25.3 89.6
Yonne 89 43.2 25.4 99.5
Territoire-de-Belfort 90 43.6 26.6 88
Essonne 91 35.1 26.3 101.3
Hauts-de-Seine 92 35.6 25.5 100.8
Seine-Saint-Denis 93 37.7 26.3 100
Val-de-Marne 94 35.6 24.6 104.2
Val-d’Oise 95 34.1 23.2 103.9
FRANCE 38 24.8 98.68 Journal of Cancer Epidemiology
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Figure 2: Map of SIR of colon-rectum cancer in men.
not the case with algorithm 2 for which heterogeneity was
observed. However, as already mentioned in section Meth-
ods, cross-validation could not be carried out to validate
estimate from algorithm 1 and thus, because of diﬃcult
formal validations of the D´ epartement-speciﬁc estimations,
we only present national estimations based on this algorithm
1.Thenationalincidencewas4,637cases,whichcorresponds
to a WASR of 8.6 cases per 100,000.
3.4. Kidney Cancer. The quality of data chaining in D´ epar-
tements with registries diﬀered according to sex. Thus,
eight D´ epartement registries were considered for men (one
registry excluded because of a 92.5% chaining rate) and ﬁve
r e g i s t r i e sf o rw o m e n( f o u rr e g i s t r i e se x c l u d e db e c a u s eo f
chaining rates ranging between 89.7% and 94.4%).
Here too, only a graphical validation of the estimations
could be carried out and, because of diﬃcult validations of
D´ epartement-speciﬁc estimations, only national estimations
are given.
As for ovary cancer and irrespective of sex, algorithm
1 performed better than algorithm 2. In 2007, the national
incidenceofkidneycancerwasestimatedat6,775inmenand
3,273 in women; the national WASR was 13.3 per 100,000 in
men but much lower (5.2 per 100,000) in women.
3.5. SIR Maps. D´ epartement-speciﬁc estimations for colon-
rectum and breast cancer are shown in Table 4 and SIR
maps of these cancers are shown in Figures 2, 3, 4. These
maps were not constructed for ovary and kidney cancers
0.754–0.928
0.928–0.978
0.978–1.022
1.022–1.075
1.075–1.236
SIR subgroups
Figure 3: Map of SIR of colon-rectum cancer in women.
because of diﬃcult formal validations of D´ epartement-
speciﬁc incidence.
Overall, no clear geographical gradient could be seen.
However,forcolon-rectumcancerinmen,thesouthwestwas
a low incidence area. This area was much larger in women.
One well-marked low-incidence area for breast cancer was
the southwest quadrant of France.
4. Discussion
To estimate the incidence of the four cancers in each
D´ epartement, case extraction from PMSI database used
two algorithms. algorithm 1 targeted all hospitalized cancer
patients; that is, those whose principal diagnosis is cancer
because of positive laboratory tests, metastasis staging,
cancer-related procedures, or sudden potentially fatal pro-
gression (exacerbation or relapse). Thus, some prevalent
cases were included along with incident cases. This is
common in incidence estimations based on hospital data
[15–17] and was conﬁrmed here: the number found in PMSI
data was higher than incident cases found in the registries
(truerwithalgorithm1thanwithalgorithm2).Nevertheless,
the PMSI cases/incident cases ratio obtained with algorithm
1 seemed somehow stable between D´ epartements, which
allowed estimations of D´ epartement-speciﬁc incidence. In
contrast,algorithm2thatusedinitialsurgicalprocedureswas
more selective; it extracted a closer number of PMSI patients
to the number of incident cases than algorithm 1. Thus,
the PMSI cases/incident cases ratio was more heterogeneous
between D´ epartements (at diﬀerent degrees according to theJournal of Cancer Epidemiology 9
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0.954–1.011
1.011–1.043
1.043–1.266
SIR subgroups
Figure 4: Map of SIR of breast cancer.
cancer site). Besides, cross-validation revealed that incidence
estimations in some D´ epartements with registries were not
valid. Indeed, with algorithm 2, the critical value of the
predictionerrorwascrossedforcolon-rectumcancerinboth
sexes and for breast cancer in women. In sum, the simpler
and less selective algorithm 1 was more adequate than
algorithm 2 to estimate D´ epartement-speciﬁc incidence.
At the national level, our estimations were in agreement
with FRANCIM projections [13], except for breast cancer
(our estimations were lower). This was expected because
estimations using incidence/mortality ratios do not take into
account the recent trend towards a slow decline of breast
cancer incidence in France [18] and in other countries [19,
20]. Our estimation made in 2007 at 50,578 new yearly cases
in France seemed thus more realistic than the 52,492 cases
stemming from FRANCIM projections. This comparison
is interesting because it shows that in average, over all
D´ epartements, our approach leads to reliable estimations.
Finally, our graphical validation cannot constitute a formal
validation because, in borderline situations, one cannot
claim a “D´ epartement eﬀect”. The graphical method would
be only as a tool to detect important departures from the
model assumptions.
PMSI data concern only hospitalized patients; thus, our
method does not apply to cancers such as skin melanomas or
basocellular cancers, which are usually treated early without
hospitalization. Besides, the method supposed identical
treatment choices in all D´ epartements; which motivated
the choice of the four cancer sites [21]. In two successive
articles on colon and rectum cancers [22, 23], Phelip et al.
have shown that surgical resection was performed in 90%
of cases without signiﬁcant geographical variation between
D´ epartements. A high variability in treatment choices leads
to problems with case-extraction from the PMSI database.
For example, in aged men, prostate cancer can be treated
by surgery, radiotherapy, or even hormone therapy alone
(without hospitalization) and, in bladder cancer, the surgical
treatment depends on the stage. If surgery is avoided, the
lack of “surgery for cancer” in the PMSI database leads to
missingness of PMSI cancer cases.
In addition, our method lays fundamentally on the
hypothesis that within a given age group, the PMSI
cases/incident cases ratio is constant between D´ epartements
whereas several factors may aﬀect that rate. First, chaining
of hospital stays is essential. Indeed, in a previous work
[7], an insuﬃcient chaining led to consider the number of
stays rather than the number of patients. Consequently, the
between-D´ epartement variability in the mean number of
stays per patient—essentially due to very diﬀerent hospi-
talization policies and coding practices—prevented correct
estimations. In 2002, the chaining rate was quite low (92%)
but improved up to 2004 (nearly 96%) because of the
implementation of a “Tariﬁcation A l’Activit´ e” (a prospective
payment system). This rate further improved nationwide up
to 2007. This high quality will soon become a norm. The use
of a single-patient identiﬁer allows keeping a single record
perpatientwhateverthenumberofhospitalstaysandinsures
a better homogeneity of PMSI data.
Variability may also stem from various coding habits
in diﬀerent health institutions because of ignorance or
misinterpretation of coding rules. A wide interinstitution
variability of the PMSI cases/incident cases ratio may lead to
aw i d eb e t w e e n - D ´ epartement variability, especially between
D´ epartements with few health institutions.
Besides, the PMSI cases/incident cases ratio reﬂects the
fact that for a given incidence level, the prevalence may vary
between D´ epartements. Indeed, diﬀerent rates of cancer-
speciﬁc survivals between D´ epartements aﬀect hospital
prevalence; thus, the number of PMSI cases. In fact, survival
in a given D´ epartement may vary with the presence/absence
of systematic screening, the existence or not of a reference
health institution [24], and the educational [25] and socioe-
conomic levels of the population [26]. If survival is high
because of complete cures, hospital prevalence and PMSI
cases will decrease, which will underestimate incidence, but
if survival is high but associated with more procedures,
hospital prevalence and PMSI cases will increase, which will
overestimate D´ epartement-speciﬁc incidence. The impact of
diﬀerent survival rates between D´ epartements on hospital
prevalence is complex to seize and undoubtedly dependent
on the cancer site under study.
Another implicit hypothesis in our method is a constant
PMSI cases/incident cases ratio from 2004 to 2007. This is
plausible because data quality of both sources over that short
period was deemed constant despite improvements in cancer
therapies that would have changed the prevalence of cancer.
Another eﬀect of time is the change in the national standards
of coding PMSI data. For example, coding palliative care as
“cancer”hasbeenreplacedbyaspeciﬁcICD-10code(Z51.5).
More recently, in 2009, the rules for the choice of the princi-
pal diagnosis have changed; the impact of that changeshould10 Journal of Cancer Epidemiology
be evaluated. Nevertheless, that impact would be limited
within the context of the four cancers under study here.
Improvements of the present method are possible. A
better followup of the same patients over several years would
exclude a number of prevalent cases. The ratio would vary
less between D´ epartements. Ideally, if all prevalent cases were
excluded, the ratio would be interpreted as the proportion of
hospitalized incident cases and would be no more aﬀected
by diﬀerent prevalence in diﬀerent D´ epartements. Another
improvementwouldbetoadddatafromthehealthinsurance
(Aﬀections Longue Dur´ ee (ALD30) database of Caisses
d’Assurance Maladie); a feasibility study of that possibility
is underway.
5. Conclusion
Using an adequate method, it seems now possible to
estimate D´ epartement-speciﬁc incidence of some cancers
for a given year. A validation procedure should accompany
these estimations. Nevertheless, this validation is only partial
because D´ epartement-speciﬁc estimations will still suﬀer the
basic assumption of similar coding practices in all hospitals.
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